|
1.
|
Jiang P, Enomoto A and Takahashi M: Cell
biology of the movement of breast cancer cells: intracellular
signalling and the actin cytoskeleton. Cancer Lett. 284:122–130.
2009. View Article : Google Scholar
|
|
2.
|
Claus EB, Stowe M and Carter D: Breast
carcinoma in situ: risk factors and screening patterns. J Natl
Cancer Inst. 93:1811–1817. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Bombonati A and Sgroi DC: The molecular
pathology of breast cancer progression. J Pathol. 223:307–317.
2011. View Article : Google Scholar
|
|
4.
|
van Golen KL: Inflammatory breast cancer:
relationship between growth factor signaling and motility in
aggressive cancers. Breast Cancer Res. 5:174–179. 2003.PubMed/NCBI
|
|
5.
|
Sahai E and Marshall CJ: RHO-GTPases and
cancer. Nat Rev Cancer. 2:133–142. 2002. View Article : Google Scholar
|
|
6.
|
Tang Y, Olufemi L, Wang MT and Nie D: Role
of Rho GTPases in breast cancer. Front Biosci. 13:759–776. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Etienne-Manneville S and Hall A: Rho
GTPases in cell biology. Nature. 420:629–635. 2002. View Article : Google Scholar
|
|
8.
|
Vega FM and Ridley AJ: Rho GTPases in
cancer cell biology. FEBS Lett. 582:2093–2101. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Takai Y, Sasaki T and Matozaki T: Small
GTP-binding proteins. Physiol Rev. 81:153–208. 2001.PubMed/NCBI
|
|
10.
|
Moon SY and Zheng Y: Rho GTPase-activating
proteins in cell regulation. Trends Cell Biol. 13:13–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Grise F, Bidaud A and Moreau V: Rho
GTPases in hepatocellular carcinoma. Biochim Biophys Acta.
1795:137–151. 2009.PubMed/NCBI
|
|
12.
|
Ching YP, Wong CM, Chan SF, et al: Deleted
in liver cancer (DLC) 2 encodes a RhoGAP protein with growth
suppressor function and is underexpressed in hepatocellular
carcinoma. J Biol Chem. 278:10824–10830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Ullmannova V and Popescu NC: Expression
profile of the tumor suppressor genes DLC-1 and DLC-2 in solid
tumors. Int J Oncol. 29:1127–1132. 2006.
|
|
14.
|
Thorsell AG, Lee WH, Persson C, et al:
Comparative structural analysis of lipid binding START domains.
PLoS One. 6:e195212011. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Liao YC and Lo SH: Deleted in liver
cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J
Biochem Cell Biol. 40:843–847. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
El-Sitt S, Khalil BD, Hanna S, El-Sabban
M, Fakhreddine N and El-Sibai M: DLC2/StarD13 plays a role of a
tumor suppressor in astrocytoma. Oncol Rep. 28:511–518.
2012.PubMed/NCBI
|
|
17.
|
Nobes CD and Hall A: Rho GTPases control
polarity, protrusion, and adhesion during cell movement. J Cell
Biol. 144:1235–1244. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Wolfenson H, Henis YI, Geiger B and
Bershadsky AD: The heel and toe of the cell’s foot: a multifaceted
approach for understanding the structure and dynamics of focal
adhesions. Cell Motil Cytoskeleton. 66:1017–1029. 2009.
|
|
19.
|
Arjonen A, Kaukonen R and Ivaska J:
Filopodia and adhesion in cancer cell motility. Cell Adh Migr.
5:421–430. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sander EE, ten Klooster JP, van Delft S,
van der Kammen RA and Collard JG: Rac downregulates Rho activity:
reciprocal balance between both GTPases determines cellular
morphology and migratory behavior. J Cell Biol. 147:1009–1022.
1999. View Article : Google Scholar
|
|
21.
|
Cox EA, Sastry SK and Huttenlocher A:
Integrin-mediated adhesion regulates cell polarity and membrane
protrusion through the Rho family of GTPases. Mol Biol Cell.
12:265–277. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kaverina I, Krylyshkina O and Small JV:
Regulation of substrate adhesion dynamics during cell motility. Int
J Biochem Cell Biol. 34:746–761. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
El-Sibai M, Pertz O, Pang H, et al:
RhoA/ROCK-mediated switching between Cdc42- and Rac1-dependent
protrusion in MTLn3 carcinoma cells. Exp Cell Res. 314:1540–1552.
2008. View Article : Google Scholar
|
|
24.
|
Banyard J, Anand-Apte B, Symons M and
Zetter BR: Motility and invasion are differentially modulated by
Rho family GTPases. Oncogene. 19:580–591. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Vial E, Sahai E and Marshall CJ: ERK-MAPK
signaling coordinately regulates activity of Rac1 and RhoA for
tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Tkach V, Bock E and Berezin V: The role of
RhoA in the regulation of cell morphology and motility. Cell Motil
Cytoskeleton. 61:21–33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Yuan BZ, Miller MJ, Keck CL, Zimonjic DB,
Thorgeirsson SS and Popescu NC: Cloning, characterization, and
chromosomal localization of a gene frequently deleted in human
liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res.
58:2196–2199. 1998.
|
|
28.
|
Yuan BZ, Durkin ME and Popescu NC:
Promoter hypermethylation of DLC-1, a candidate tumor suppressor
gene, in several common human cancers. Cancer Genet Cytogenet.
140:113–117. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Durkin ME, Yuan BZ, Zhou X, et al: DLC-1:a
Rho GTPase-activating protein and tumour suppressor. J Cell Mol
Med. 11:1185–1207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Yuan BZ, Zhou X, Durkin ME, et al: DLC-1
gene inhibits human breast cancer cell growth and in vivo
tumorigenicity. Oncogene. 22:445–450. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Ng IO, Liang ZD, Cao L and Lee TK: DLC-1
is deleted in primary hepatocellular carcinoma and exerts
inhibitory effects on the proliferation of hepatoma cell lines with
deleted DLC-1. Cancer Res. 60:6581–6584. 2000.PubMed/NCBI
|
|
32.
|
Kim TY, Vigil D, Der CJ and Juliano RL:
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in
regulation of the cytoskeleton and cell motility. Cancer Metastasis
Rev. 28:77–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Zhong D, Zhang J, Yang S, et al: The SAM
domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J
Cell Sci. 122:414–424. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Shih YP, Takada Y and Lo SH: Silencing of
DLC1 upregulates PAI-1 expression and reduces migration in normal
prostate cells. Mol Cancer Res. 10:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Cao X, Voss C, Zhao B, Kaneko T and Li SS:
Differential regulation of the activity of deleted in liver cancer
1 (DLC1) by tensins controls cell migration and transformation.
Proc Natl Acad Sci USA. 109:1455–1460. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Massague J: TGFbeta in Cancer. Cell.
134:215–230. 2008. View Article : Google Scholar
|
|
37.
|
Wang Y and McNiven MA: Invasive matrix
degradation at focal adhesions occurs via protease recruitment by a
FAK-p130Cas complex. J Cell Biol. 196:375–385. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Pille JY, Denoyelle C, Varet J, et al:
Anti-RhoA and anti-Rh˚C siRNAs inhibit the proliferation and
invasiveness of MDA-MB-231 breast cancer cells in vitro and in
vivo. Mol Ther. 11:267–274. 2005.PubMed/NCBI
|
|
39.
|
Wu M, Wu ZF, Rosenthal DT, Rhee EM and
Merajver SD: Characterization of the roles of RHOC and RHOA GTPases
in invasion, motility, and matrix adhesion in inflammatory and
aggressive breast cancers. Cancer. 116:2768–2782. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Sahai E and Marshall CJ: Differing modes
of tumour cell invasion have distinct requirements for Rho/ROCK
signalling and extracellular proteolysis. Nat Cell Biol. 5:711–719.
2003. View Article : Google Scholar : PubMed/NCBI
|
